Back to Search
Start Over
mTOR, a new potential target for chronic pain and opioid-induced tolerance and hyperalgesia.
- Source :
- Molecular Pain; 2015, Vol. 11 Issue 1, p1-7, 7p, 3 Diagrams
- Publication Year :
- 2015
-
Abstract
- Chronic pain is a major public health problem with limited treatment options. Opioids remain a routine treatment for chronic pain, but extended exposure to opioid therapy can produce opioid tolerance and hyperalgesia. Although the mechanisms underlying chronic pain, opioid-induced tolerance, and opioid-induced hyperalgesia remain to be uncovered, mammalian target of rapamycin (mTOR) is involved in these disorders. The mTOR complex 1 and its triggered protein translation are required for the initiation and maintenance of chronic pain (including cancer pain) and opioid-induced tolerance/hyperalgesia. Given that mTOR inhibitors are FDA-approved drugs and an mTOR inhibitor is approved for the treatment of several cancers, these findings suggest that mTOR inhibitors will likely have multiple clinical benefits, including anticancer, antinociception/anti-cancer pain, and antitolerance/hyperalgesia. This paper compares the role of mTOR complex 1 in chronic pain, opioid-induced tolerance, and opioid-induced hyperalgesia. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 17448069
- Volume :
- 11
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Molecular Pain
- Publication Type :
- Academic Journal
- Accession number :
- 108276505
- Full Text :
- https://doi.org/10.1186/s12990-015-0030-5